Quarterly report pursuant to Section 13 or 15(d)

Development Awards and Deferred Revenue (Details Narrative)

v3.19.1
Development Awards and Deferred Revenue (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 26, 2018
Apr. 20, 2015
Mar. 31, 2019
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Development Award [Line Items]              
Amount received upon achievement     $ 27,000,000 $ 27,000,000   $ 1,462,503  
Revenue       $ 1,885,682 $ 950,442    
Warrant exercisable shares of common stock     1,083,500 1,083,500      
Additional paid in capital, fair value of warrant issued         6,215,225    
Cystic Fibrosis Foundation Warrants [Member]              
Development Award [Line Items]              
Revenue       $ 18,784,775      
Warrant to purchase of common stock 1,000,000            
Warrant exercisable price per share $ 13.20            
Warrant exercisable shares of common stock 500,000            
Warrant expires date Jan. 26, 2025            
Additional paid in capital, fair value of warrant issued       6,215,225      
Maximum [Member]              
Development Award [Line Items]              
Amount received upon achievement           12,500,000  
2015 CFFT Award Agreement [Member]              
Development Award [Line Items]              
Revenue           $ 2,440,195
2015 CFFT Award Agreement [Member] | Oral Anti-inflammatory Drug [Member]              
Development Award [Line Items]              
Amount received upon achievement   $ 5,000,000          
2015 CFFT Award Agreement [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]              
Development Award [Line Items]              
Payment due period after the first commercial sale   90 days          
Royalty payment, sales target   $ 500,000,000          
2015 CFFT Award Agreement [Member] | Maximum [Member]              
Development Award [Line Items]              
Development award received   5,000,000          
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Commercialization of the Product [Member]              
Development Award [Line Items]              
Royalty payable   25,000,000          
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]              
Development Award [Line Items]              
Royalty payable   5,000,000          
2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Transfer Sale or Licensing [Member]              
Development Award [Line Items]              
Royalty payable   $ 15,000,000          
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]              
Development Award [Line Items]              
Development award received $ 25,000,000            
Investment Agreement [Member]              
Development Award [Line Items]              
Revenue       1,885,682 $ 950,442    
Reclassified to contract asset and classified in prepaid expenses       25,000,000      
Investment Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member] | 2018 CFF Award [Member]              
Development Award [Line Items]              
Proceeds from Royalty       2,700,000      
Upfront payment, received from related party       27,000,000      
Investment Agreement [Member] | Phase 2b Clinical Trial [Member]              
Development Award [Line Items]              
Amount received upon achievement     $ 12,500,000 12,500,000      
Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member]              
Development Award [Line Items]              
Warrant exercisable shares of common stock 500,000            
Investment Agreement [Member] | April 2019 [Member] | Phase 2b Clinical Trial [Member]              
Development Award [Line Items]              
Amount received upon achievement     5,000,000 $ 5,000,000      
Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member]              
Development Award [Line Items]              
Royalty payment percentage       10.00%      
Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member]              
Development Award [Line Items]              
Upfront payment, received from related party     27,000,000 $ 27,000,000      
Consideration received on milestone payments     $ 173,000,000        
Royalty term description     Ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party's insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days' notice.        
Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member] | 2018 CFF Award [Member]              
Development Award [Line Items]              
Royalty payable       $ 27,000,000